![]() | ![]() |
Formats:
|
||||||||||||||||||||||||||||
Copyright © 2007 by The American Society for Cell Biology Constitutively Active Akt Induces Ectodermal Defects and Impaired Bone Morphogenetic Protein Signaling *Molecular Oncology Unit, Division of Biomedicine, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, E-28040 Madrid, Spain; ‡Department of Carcinogenesis, Science Park-Research Division, University of Texas M.D. Anderson Cancer Center, Smithville, TX 78957; §Department of Veterinary Clinical Sciences, Veterinary Pathology Unit, Veterinary Faculty, University of Santiago de Compostela, E-27002 Lugo, Spain; and ‖Flow Cytometry Unit, Division of Hematopoiesis, CIEMAT, E-28040 Madrid, Spain M. Bishr Omary, Monitoring Editor Corresponding author.Address correspondence to: John DiGiovanni (Email: jdigiovanni/at/mdanderson.org) or Jesús M. Paramio (Email: jesusm.paramio/at/ciemat.es) † These authors contributed equally to this work.Received August 7, 2007; Revised September 21, 2007; Accepted October 17, 2007. Abstract Aberrant activation of the Akt pathway has been implicated in several human pathologies including cancer. However, current knowledge on the involvement of Akt signaling in development is limited. Previous data have suggested that Akt-mediated signaling may be an essential mediator of epidermal homeostasis through cell autonomous and noncell autonomous mechanisms. Here we report the developmental consequences of deregulated Akt activity in the basal layer of stratified epithelia, mediated by the expression of a constitutively active Akt1 (myrAkt) in transgenic mice. Contrary to mice overexpressing wild-type Akt1 (Aktwt), these myrAkt mice display, in a dose-dependent manner, altered development of ectodermally derived organs such as hair, teeth, nails, and epidermal glands. To identify the possible molecular mechanisms underlying these alterations, gene profiling approaches were used. We demonstrate that constitutive Akt activity disturbs the bone morphogenetic protein-dependent signaling pathway. In addition, these mice also display alterations in adult epidermal stem cells. Collectively, we show that epithelial tissue development and homeostasis is dependent on proper regulation of Akt expression and activity. INTRODUCTION A large number of processes in the cell are modulated by the protein kinase Akt, also known as protein kinase B (PKB). In particular, this kinase has been widely involved in the control of cell survival and apoptosis, proliferation, cell cycle progression, glucose metabolism, and protein translation (Brazil et al., 2004 ). Three Akt isoforms sharing common structural features (Hanada et al., 2004 ) have been found in mammals (Akt1, Akt2, Akt3). Although the relevance of Akt signaling in cancer is widely recognized (Bellacosa et al., 2005 ; Manning and Cantley, 2007 ), its involvement in development has only recently been highlighted. Akt1 and Akt2 knockout (KO) mice are viable and exhibit mild phenotypes characterized by growth retardation and diabetes (Chen et al., 2001 ; Cho et al., 2001 ), suggesting functional redundancy among Akt isoforms. Further proof of these overlapping roles comes from analysis of compound mutant mice. Akt1 and Akt2 double KO mice displayed a much more severe phenotype: dwarfism, impaired skin development, delayed bone development, reduced adipogenesis, and early lethality after birth (Peng et al., 2003 ). More recently, mice with combined mutant alleles of Akt1 and Akt3 have also been generated. Double KO of Akt1 and Akt3 causes embryonic lethality at around embryonic days 11 and 12, and Akt1−/−;Akt3−/− mice have severe developmental defects in the cardiovascular and nervous systems (Yang et al., 2005 ). Akt1−/−;Akt3+/− mice display multiple defects in the thymus, heart, and skin and die within several days after birth, whereas Akt1+/−;Akt3−/− mice are viable (Yang et al., 2005 ). These data demonstrate that the three Akt isoforms have overlapping functions but also may have unique functions in specific organs.Besides the skin phenotype observed in different compound-deficient mice, several lines of evidence have highlighted the importance of the phophoinositide 3 kinase (PI3K)/Akt pathway in epidermis. Of particular interest is the relevant role of Akt during mouse skin carcinogenesis. We have demonstrated that Akt is a key molecule in insulin growth factor 1 (IGF-1)-mediated mouse skin tumor promotion (Wilker et al., 2005 ). In addition, Akt exerts essential roles in two-stage carcinogenesis protocols affecting tumor proliferation and apoptosis (Segrelles et al., 2002 ) and also modulates the tumor-stroma cross-talk leading to an increase in angiogenesis (Segrelles et al., 2004 ). Recently, using cultured cell systems, we provided evidence indicating that the functions of Akt in epidermal tumors are exerted by transcriptional and posttranscriptional mechanisms and show several parallels with human head and neck squamous cell carcinomas (Segrelles et al., 2006 ). Of relevance, we observed that increased Akt expression modulates β-catenin and ΔNp63 expression, two essential modulators of epidermal development, in this system (Segrelles et al., 2006 ).To further explore the role of Akt in skin, we have generated transgenic mice expressing either a wild-type form of Akt1 (Aktwt) or a form of Akt1 that is constitutively activated by means of a myristoylation sequence (myrAkt), directed to the basal layer of the stratified epithelia by the K5 promoter (Segrelles et al., 2007 ). These approaches, together with the tissue-specific knock out of PTEN tumor suppressor gene, have been widely used to explore the functions of the Akt signaling pathway in vivo (Yang et al., 2004 ). Notably, there are functional differences among these three approaches. Because PTEN is a negative modulator of PI3K signaling, elimination of PTEN leads to the permanent up-regulation of the PI3K pathway, whereas increased expression of wild-type Akt leads to the amplification of PI3K signaling, and the expression of constitutively active Akt generates a permanent, PI3K-independent signal. Although performing our previous analysis, we observed that many of the founders expressing K5myrAkt, but not those expressing K5Aktwt, displayed developmental defects in multiple ectodermal organs in parallel with the level of transgene expression and Akt activity. Here we have characterized these developmental alterations. We provide evidence that deregulated Akt activity in stratified epithelia mediated by myrAkt expression leads to aberrant bone morphogenetic protein 4 (BMP4) signaling and altered adult epidermal stem cell homeostasis.MATERIALS AND METHODS Transgenic Mouse Production and Maintenance Wild-type mouse Akt cDNA (obtained from Dr. A. Bellacosa, Fox Chase Cancer Center) or myrAkt (obtained from Dr. S. Gutkind, National Institute of Dental and Craniofacial Research, NIH) were placed under a 5.2-kb fragment of the BK5 promoter into the SnaBI site between the rabbit β-globin intron and polyadenylation sequences from a vector previously described (Bol et al., 1998 ). Orientation and integrity of the inserts were confirmed by restriction digests. Purified fragments were used in microinjection. Mice were genotyped using primers specific for β-globin on genomic DNA isolated from tails, as previously described (Bol et al., 1998 ). Transgenic and control mice in a C57BL/DBA/FVB mixed background were housed in a 12/12 light/dark cycle at 24°C and given standard mouse chow and water ad libitum. In some cases, where alterations in oral cavity or teeth were observed, food was supplemented with jelly. In addition to the founders, at least 40 mice of each transgenic line or controls were analyzed in search for developmental defects.Histology and Akt Kinase Analyses For histological analysis, samples were fixed in Formalin and embedded in paraffin before sectioning. Sections of 5 μm were cut and stained with H&E. At least five different samples were analyzed for each time point. The expression of BMP2 (1/200 diluted mAb; Abcam, Cambridge, UK), BMP4 (1/50 diluted goat polyclonal; AbCam) and ΔNp63 (1/200 diluted mAb 4A4; Santa Cruz Biotechnology, Santa Cruz, CA) was monitored in deparaffined sections using conventional protocols. For expression of active Akt (phospho Ser 473, 1/50 diluted; Cell Signaling, Beverly, MA), phospho Smad1/5/8 (phosphorylated in Ser463 and 465, 1/100 diluted; Cell Signaling), Foxo3a (1/200 diluted; Upstate, Lake Placid, NY), and BMPRIA (1/100; Santa Cruz Biotechnology), the slides were microwaved for 10 min after deparaffinization to enhance the staining. Keratin 15 (mouse mAb LHK15; Neomarkers, Lab Vision, Fremont, CA; diluted 1/50), and CD34 (rat mAb; eBioscience, San Diego, CA; diluted 1/50) were monitored in 70% ethanol-fixed tissues by double immunofluorescence. Before incubation overnight at 4°C with primary antibodies diluted in bovine serum albumin (BSA)/phosphate-buffered saline (PBS), sections were incubated with 5% horse serum for 45 min to block the Fc receptor in tissue and then washed three times with sterile PBS (pH 7.5). Horseradish peroxidase–, Texas red–, or fluorescein isothiocyanate–conjugated secondary antibodies were purchased from Jackson ImmunoResearch (West Grove, PA) and used at dilutions of 1/4000, 1/500, and 1/100, respectively. Peroxidase was visualized using a DAB kit (Vector, Burlingame, CA). Control slides were obtained by replacing primary antibodies with PBS (data not shown). Akt activity in mouse skin was determined after immunoprecipitation with anti-Akt (Santa Cruz Biotechnology, C-20 antibody 1 ml/25 mg protein) essentially as previously described (Segrelles et al., 2002 ), using histone 2B (H2B; Roche Molecular Biochemicals, Indianapolis, IN) as the substrate for Akt or by Western blot (see below). Autoradiograms were scanned and subsequently quantified using a Phosphorimager (Bio-Rad, Richmond, CA).Scanning Electron Microscope Studies of Hair Shafts Hair shafts from the dorsal skin of 30-d-old transgenic and nontransgenic littermates were fixed in 2.5% glutaraldehyde in 0.1 M phosphate buffer (pH 7.5). After dehydration, samples were dried by critical point drying (Balzers, Hudson, NH; CPD020), coated with gold palladium by a Jeol JFC-1100 Ion Sputter, and examined with a Jeol JSM-T220A scanning electron microscope (SEM; Peabody, MA). At least 10 samples from each genotype were analyzed. RNA Purification and Affymetrix Mouse Gene Chip 430A Analysis Mouse skin tissue, obtained 30 d after birth, was preserved in RNAlater (Ambion, Austin, TX) and disrupted and homogenized using Mixer Mill MM301 (Retsch). Total RNA was extracted and purified from 30 mg of skin using RNeasy Fibrous Tissue Mini kit (Qiagen, Chatsworth, CA) following the manufacturer's recommendations. The integrity of the RNA populations was tested in the Bioanalyzer (Agilent, Wilmington, DE). Two (transgenic mouse lines L60, L84 and LA) or three pools (control mice) from RNA whole skin extracts of same genotype were done and analyzed, individually, in mouse microarrays. We exported CEL files from Affymetrix GCOS software (Santa Clara, CA), and using the web-based tool Gene Expression Profile Analysis Suite (GEPAS, http://www.gepas.org; Vaquerizas et al., 2005 ), we subtracted the background intensity values with RMA (Irizarry et al., 2003 ), normalized the chips using quantile method (Bolstad et al., 2003 ), and finally log2-transformed and mean-centered the intensity values. Differentially expressed genes with normal variability were extracted between the four mouse genotypes with CLEAR test (2183 Affymetrix probes, p < 0.05; Valls et al., 2007 ). Further analyses were performed using the MeV software (Saeed et al., 2003 ). The selection of genes belonging to clusters 1–4 was made using Template Matching (Pearson R > 0.8, p < 0.01; Pavlidis and Noble, 2001 ). Genes selected in more than one cluster were included in the cluster in which they displayed the best R and p values. The cluster Gene Ontology (GO) analysis of Biological Processes using DAVID software (Dennis et al., 2003 ; http://david.abcc.ncifcrf.gov/home.jsp) from the National Institute of Allergy and Infectious Diseases/NIH was used to identify functional categories for each cluster. The search for GO terms was made using all themes, listed by p value based on EASE score (Hosack et al., 2003 ) and manually curated. EASE score identifies functional categories overrepresented in a gene list relative to the representation within the proteome of a given species.(Hosack et al., 2003 ). Pathway Architect software (Stratagene, La Jolla, CA) was used to identify and characterize possible pathways affected by specific alterations in gene expression. Gene expression microarray dataset has been submitted in GEO database under the accession number GSE9054.Western Blot Analysis Extracts, prepared from skin of 30-d-old mice, were ground with a mortar on liquid nitrogen and homogenized in buffer P (Tris, pH 7.5, NaCl 150 mM, EDTA 1 mM, EGTA 1 mM, β-glycerophosphate 40 mM, sodium orthovanadate 1 mM, PMSF 0.1 mM, aprotinin 2 mg/ml, leupeptin 2 mg/ml, NP-40 1%). Total protein (35 μg) from at least three age- and genotype-matched pooled skin samples was used for NuPAGE 4–12% Bis-Tris Gel (Invitrogen, Carlsbad, CA), transferred to nitrocellulose membrane (Invitrogen), and probed with primary antibodies against Akt1/2 (Santa Cruz Biotechnology; 1/500), phosphorylated Akt (Ser 473, diluted 1/50 and Thr 308, diluted 1/10; Cell Signaling), BMPR1 (Santa Cruz Biotechnology; 1/100), BMP4 (Abcam; 1/300), p63 (Santa Cruz Biotechnology; 1/500), and phospho-Smad1/5/8 (recognizing Smad1/5/8 phosphorylated in Ser463 and 465; Cell Signaling; 1/500). Actin (Santa Cruz Biotechnology; 1/1000) was used to normalize protein loading. Secondary antibodies (anti-rabbit, anti-mouse, or anti-goat IgG) were purchased from Jackson ImmunoResearch. Chemiluminescence was performed using manufacturer's recommendations (Pierce, Rockford, IL). Label-retaining Cell Analysis Ten-day-old nontransgenic and myrAkt pups (six mice of each class) were injected with BrdU (20 μl of a 12.5 mg/ml dilution in 0.9% NaCl every 12 h for a total of four injections). Skin sections were collected at 30 d after the last injection and bromodeoxyuridine (BrdU) incorporation was measured as percentage of hair follicles (HF) containing positive cells as previously reported (Ruiz et al., 2004 ). Experiments were performed in triplicate (n ≥ 3 per group) and at least 100 follicles were scored in each section.Fluorescence-activated Cell Sorting Analysis For each experiment, dorsal skin of four adult animals of each genotype was shaved and treated with trypsin to separate dermis from epidermis. Cell suspensions were strained (40 -μm nylon, Falcon, Oxnard, CA) and stained in PBS containing 2% fetal bovine serum with anti-CD34 coupled to biotin (BD-PharMingen, San Diego, CA) and anti-α6 integrin (CD49f) coupled to PE (PharMingen). Cells were washed and stained with streptavidin-Tricolor (Caltag Laboratories, Burlingame, CA) and washed again. Cells were resuspended in PBS containing 2 μg/ml propidium iodide to exclude dead cells and analyzed in an EPICS XL flow cytometer (Coulter Electronics, Hialeah, FL). RESULTS Ectodermal Alterations in myrAkt Transgenic Mice The K5 promoter was used to target the expression of wild-type Akt1 (Aktwt) or permanently activated Akt1 (myrAkt) to the basal layer of the mouse stratified epithelia. The overall epidermal phenotype and tumor susceptibility of these mice has been reported elsewhere (Segrelles et al., 2007 ). It is worth mentioning that, because of the deleterious effects of myrAkt or wtAkt expression, it was impossible to establish lines from many of the founders. Eventually, we were able to establish two lines with different expression levels of the myrAkt transgene (lines 60 and 84, hereafter L60 and L84) and one line expressing the wtAkt transgene (Line A, hereafter LA). Our analysis was then focused on these three lines and six myrAkt founders.MyrAkt founders and L84 transgenic mice showing high levels of Akt kinase activity (Figure 1
With respect to hair, we observed alopecia in the snout, face, and back skin and loss of vibrissae in myrAkt founders with high levels of Akt activity, in myrAkt L84 mice, and sporadically in L60 mice (Figure 2
Another characteristic displayed by L84 transgenic mice and some founders were long and fragile nails (Figure 3
With respect to teeth, most of L84 transgenic mice and some founders showed overgrowth and thinning of the incisors (Figure 4
We also characterized alterations in other ectodermal-derived structures. We observed a significant hyperplasia of the meibomian glands (denoted by mb in Figure 5
Alterations in Gene Expression Mediated by De-regulated Akt Activity in Skin The development of ectodermal organs is controlled by multiple pathways involving numerous genes. Most of these pathways modulate the process of hair cycling. The ectodermal and hair cycle defects observed in the transgenic mice suggested that increased and deregulated Akt activity leads to altered expression of genes involved in these developmental pathways. To gain a deeper insight into this aspect, we performed global expression profiling of paired RNA samples from whole skin extracts of transgenic (L60, L84, and LA) and nontransgenic mice at 30 d after birth. The LA mice did not display the ectodermal alterations observed in L84, and in L60 mice only sporadic alopecia was detected in the snout, face, and back skin; none of these transgenic lines displayed hair cycle defects (Figure 2
To identify possible functional alterations in the different skin samples, we analyzed the biological functions of the 173 genes mentioned above using DAVID software (Dennis et al., 2003 ; Table 2). Interestingly, the concept “development” appears as significantly represented in the clusters including those genes that only showed altered expression in L84 skin samples (clusters 3 and 4). Utilizing the Entrez gene database, we narrowed the dataset to those genes that were involved in skin or ectodermal morphogenesis (Table 3). Overall, these data indicate that deregulated Akt activity results in gene expression changes that can modulate epithelial development.
Microarray data were further analyzed using Pathway Architect (Stratagene) to identify and characterize possible signaling pathways affected by specific alterations in gene expression. This analysis revealed that the global expression changes modify BMP4 signaling. In this regard, not only was the Bmp4 gene specifically down-regulated, but also negative regulators of BMP signaling such as Egf (Nonaka et al., 1999 ) and Twsg1 (Scott et al., 2001 ) were up-regulated. In addition, several genes found in these clusters are involved in BMP signaling (Figure 6The forkhead transcription factor family has been widely described as a target of Akt (Burgering and Kops, 2002 ). Direct phosphorylation of these factors by Akt results in their cytoplasmic retention and inactivation, inhibiting the expression of forkhead transcription factor-regulated genes (Burgering and Kops, 2002 ). We thus studied whether the expression and localization of Foxo3a, a representative member of this family, is affected in the epidermis of the different transgenic mice by postnatal day (pnd) 28. In control, nontransgenic mice (Figure 6 ), the expression of Akt, upon a certain threshold, leads to the reduction and cytoplasmic localization of Foxo3a in keratinocytes (Segrelles et al., 2006 ). This might help to explain, at least in part, some of the changes observed in microarray analyses.Altered BMP Signaling Mediated by myrAkt in Skin BMP signaling is thought to perform multiple functions in the regulation of skin appendage morphogenesis and the postnatal growth of HFs (Botchkarev, 2003 ). BMPs function by binding type 1 (BMPR1A and BMPR1B) and type 2 (BMPR2) transmembrane serine/threonine kinase receptors, resulting in phosphorylation of the intracellular proteins Smad 1, 5, and 8. Therefore, to further confirm the possible alterations in BMP signaling, we carried out a detailed histology analysis of several components of this pathway.As shown in Figure 7
We also examined the expression and localization of BMPRIA and phospho-Smad1 (Ser463 and Ser465). By full anagen (pnd 28), phospho-Smad staining was present in cells of the medulla, cortex, and cuticle of the hair shaft in nontransgenic and LA mice (Figure 8 ; Andl et al., 2004 ; Yuhki et al., 2004 ; Sharov et al., 2005 ). In contrast, phospho-Smad staining in myrAkt transgenic mice was faint, and only a few cells expressed very low amounts at the tip of the hair (Figure 8 ; Andl et al., 2004 ; Yuhki et al., 2004 ; Sharov et al., 2005 ), whereas in myrAkt L84 mice (Figure 8
Finally, we also studied the possible changes in the expression and localization of ΔNp63. This protein is an ectoderm-specific direct transcriptional target of BMP signaling (Bakkers et al., 2002 ) and is essential for skin development (Mills et al., 1999 ; Yang et al., 1999 ), and it can be induced by increased Akt activity (Barbieri et al., 2003 ; Segrelles et al., 2006 ). Compared with nontransgenic mice (Figure 8Deregulated Akt Activity Alters Epidermal Stem Cell Homeostasis There are several lines of evidence indicating that BMP signaling may influence the behavior of epidermal stem cells (Sharov et al., 2006 ; Zhang et al., 2006b ; Kobielak et al., 2007 ) It has also been shown that other adult stem cell populations, for example, as in hematopoietic tissue (Rossi and Weissman, 2006 ) may be impacted by PTEN/Akt pathway signaling. Because the K5 promoter is also active in these cells, we have thus studied possible alterations in the stem cell population in the skin of L84 transgenic mice. Initially we determined the expression of two putative epidermal stem cell markers, K15 and CD34 (Liu et al., 2003 ; Cotsarelis, 2006 ). The pattern of double immunofluorescence staining suggested an increase in the population of cells in the hair follicle of L84 (Figure 9 ; Taylor et al., 2000 ). In L84 skin we found a consistent increase in the number of labeled cells 30 d after BrdU administration (Figure 9 ; Blanpain and Fuchs, 2006 ). These analyses demonstrate that the proportion of α6+CD34+ cells is similar between control and L84 skin samples; however, L84 epidermis had a dramatic increase in the population characterized as α6low CD34+ at the expense of a partial reduction in the α6high CD34+ cell population (Figure 9
DISCUSSION In the current study we present data that strongly support the hypothesis that increased and deregulated Akt activity, triggered by myrAkt expression, provokes dramatic alterations in ectodermal organ development. Collectively, these findings support the conclusions that Akt is an important mediator of epithelial homeostasis. The fact that increased wild-type Akt expression (as in wtAkt mice), which requires upstream control elements to become fully activated (Segrelles et al., 2007 ), does not lead to a similar phenotype points to a finely regulated mechanism of control affecting Akt in the development of these organs. Our results are in agreement with the reported alterations found in different mouse models of Akt deficiency (Di-Poi et al., 2002 ; Peng et al., 2003 ; Yang et al., 2005 ) and the keratinocyte-specific null mutation of epidermal Pten (Suzuki et al., 2003 ). Of note, data obtained from double Akt KO mice, besides arguing for partially overlapping functions of Akt isoforms in vivo, also revealed that some functions of Akt are only discernible when total Akt levels are below a critical threshold in specific cell types and tissues (Dummler et al., 2006 ). Further evaluation of ectodermal derived organs in compound Akt KO mice may reveal additional roles.The Akt signaling pathway has been widely studied in the context of carcinogenesis (Manning and Cantley, 2007 ) and is associated with increased cell proliferation and survival. Consistently, these functions are altered in L84 mice and also in LA and in L60 (Segrelles et al., 2007 ); however, the major developmental defects are primarily found in L84 mice and several founders. This would indicate that the observed development defects due to increased Akt activity can be delineated from proliferative or antiapoptotic effects. We have taken this aspect as a starting hypothesis for the analysis of the microarray data. Indeed, the consideration of genes that do not display altered expression in LA epidermis certainly restricts the analyses. The list of genes found is relatively small and includes multiple genes previously associated with ectoderm or skin development. Furthermore, in unconstrained analysis of possible pathways involved, we detected the BMP-dependent pathway, indicating that this may be a major mediator in the skin phenotypic alterations found in myrAkt mice. The possibility that this pathway is also a target mediating other ectodermal alterations seems plausible but undoubtedly will require further investigations.It is widely recognized that BMP signaling is required for proper development of several ectodermal structures (reviewed in Jernvall and Thesleff, 2000 ; Botchkarev, 2003 ). Of note, cre-mediated mutation of the BMPR1A gene causes altered tooth morphogenesis, defective postnatal development of HFs, and abnormal nail growth (Andl et al., 2004 ) and leads to the formation of epidermal tumors (Kobielak et al., 2003 ; Andl et al., 2004 ; Sharov et al., 2006 ; Zhang et al., 2006b ), probably through the altered homeostasis of epidermal stem cells (Sharov et al., 2006 ; Zhang et al., 2006b ; Kobielak et al., 2007 ). In agreement, we also observed the development of epithelial tumors in Akt transgenic mice that in many cases were associated with hair follicle structures (Segrelles et al., 2007 ). Although epidermal-specific deletion of the Bmpr1a gene or Noggin overexpression caused severe alterations in the expression of several genes associated with development and cell cycle (Kobielak et al., 2003 ; Andl et al., 2004 ; Sharov et al., 2006 ; Zhang et al., 2006b ), our microarray analysis did not produce similar results. This difference may be due to the fact that ablation of BmprIa or Noggin overexpression completely abrogates BMP signaling, whereas our data support a possible deregulation together with decreased signaling rather than complete inhibition. As an alternative explanation, searching for genes displaying a selected pattern of expression may obscure or lead to an incomplete analysis of the data. Indeed, as mentioned above, the genes found through the unrestricted analysis of the microarray data also included most of the genes reportedly altered in BmprIa conditional KO and Noggin transgenic mice. Nevertheless this group of genes was also altered in wtAkt transgenic mice that do not display ectodermal defects.Several lines of evidence have previously shown an association between BMP and PI3K/Akt signaling pathways (Waite and Eng, 2003 ; He et al., 2004 ; Tian et al., 2005 ). In particular it has been shown that altered BMP signaling can, through the modulation of PTEN expression and activity, control the activity of the PI3K/Akt signaling pathway (Tian et al., 2005 ; Zhang et al., 2006b ; Kobielak et al., 2007 ). The present data complement these observations and show through microarray and histology analyses that deregulated Akt activity affects BMP signaling and, as an overall consequence, the BMP pathway is at least partially inhibited. Furthermore, the existence of an autoregulatory loop between BMP and PI3K/PTEN/Akt signaling may exist such that each element is subject to the control of the other, and importantly, disruption of this balance may lead to altered ectodermal development and tumor formation. The molecular bases of this alteration in Bmp4 expression are not known at present; however, among the multiple regulators of Bmp4 gene expression there are several putative candidates that can be modulated by Akt activity. In this regard, p65 RelA, which can be activated by Akt (Madrid et al., 2000 , 2001 ), is a transcriptional repressor of Bmp4 gene expression in vivo (Zhu et al., 2007 ), whereas Bmp4 transcription is activated by forkhead and NKX2 transcription factors (Zhu et al., 2004 ; Begum et al., 2005 ), which are inactivated by Akt (Burgering and Kops, 2002 ; Naito et al., 2003 ). In this regard, the altered expression and distribution of Foxo3a observed in L84 epidermis might explain the reduced expression of Bmp4. Further studies will help to clarify the functional impact of Akt activity on Bmp4 expression.Many of the alterations observed in the ectodermal organs of myrAkt mice were similar to the defects present in mice resembling human ectodermal dysplasia syndromes (Thesleff, 2006 ). The possibility that Akt may be involved in these disorders is very intriguing and would certainly merit further investigations. In some cases this group of diseases is associated with altered ΔNp63 expression (Koster and Roop, 2004 ). The finding that expression level of this protein was not altered in myrAkt transgenic mice relative to nontransgenic mice indicates that other targets of Akt kinase may be responsible for the observed phenotype. In this regard, the previously reported cross talk between the glucocorticoid receptor and Akt (Leis et al., 2004 ) and the involvement of the glucocorticoid receptor in certain ectodermal dysplasia syndromes (Perez et al., 2001 ; Cascallana et al., 2005 ) reinforces the possibility that Akt may also be involved in some of these disorders.In the current study we observed that deregulated Akt activity results in altered homeostasis of adult epidermal stem cells. This result is in agreement with the reported involvement of the PTEN/Akt pathway in the maintenance of other adult stem cells (Li et al., 2002 , 2003 ; Cheung and Mak, 2006 ; Rossi and Weissman, 2006 ; Yilmaz et al., 2006 ; Zhang et al., 2006a ). On the other hand, the alterations in stem cells observed in the epidermis of myrAkt mice also agree with the reported modulation of these cells by BMP signaling in epidermis and other tissues (Kobielak et al., 2003 ; Rajan et al., 2003 ; He et al., 2004 ; Zhang et al., 2006b ; Kobielak et al., 2007 ). Unexpectedly, we also observed that expression of myrAkt specifically affects the subpopulation of epidermal stem cells characterized by low integrin α6 expression. It has been reported that this suprabasal cell population is derived from that which maintains basal lamina contact and arises only after the start of the first postnatal hair cycle (Blanpain et al., 2004 ). Our data implicate that Akt may affect the transition between these two cell populations and would suggest that Akt may control the cross talk between stem cells and the niche microenvironment.Collectively, we present evidence that ectodermal organ development is dependent on accurate Akt signaling and that deregulation of this activity results in altered development of these organs, which in the case of skin proceeds through altered BMP signaling and affects epidermal stem cell population. [Supplemental Materials]
ACKNOWLEDGMENTS We express our gratitude to Jesús Martínez and the personnel of the animal facility of CIEMAT for the excellent care of the animals and to Pilar Hernández (CIEMAT) for the histological preparations. This work is partially supported by Grants SAF2002–01037 (MCYT), Oncocycle (CAM), ISCIII-RETIC RD06/0020 (MSC), SAF2005–00033 (MCYT) and Oncology Program from La Caixa Foundation to J.M.P. and by National Institutes of Health Grant CA 37111, National Institute of Environmental Health Sciences Center Grant ES00784, and Cancer Center Support Grant CA16672 to J.D. M.M. is recipient of a predoctoral fellowship form FIS-BEFI (BF03-00201). Footnotes This article was published online ahead of print in MBC in Press (http://www.molbiolcell.org/cgi/doi/10.1091/mbc.E07-08-0764) on October 24, 2007. REFERENCES
|
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||||||||||||||||||||||||||
Trends Biochem Sci. 2004 May; 29(5):233-42.
[Trends Biochem Sci. 2004]Biochim Biophys Acta. 2004 Mar 11; 1697(1-2):3-16.
[Biochim Biophys Acta. 2004]Adv Cancer Res. 2005; 94():29-86.
[Adv Cancer Res. 2005]Cell. 2007 Jun 29; 129(7):1261-74.
[Cell. 2007]Genes Dev. 2001 Sep 1; 15(17):2203-8.
[Genes Dev. 2001]Mol Carcinog. 2005 Oct; 44(2):137-45.
[Mol Carcinog. 2005]Oncogene. 2002 Jan 3; 21(1):53-64.
[Oncogene. 2002]Carcinogenesis. 2004 Jul; 25(7):1137-47.
[Carcinogenesis. 2004]Oncogene. 2006 Feb 23; 25(8):1174-85.
[Oncogene. 2006]Cancer Res. 2007 Nov 15; 67(22):10879-88.
[Cancer Res. 2007]Biochem Soc Trans. 2004 Apr; 32(Pt 2):350-4.
[Biochem Soc Trans. 2004]Mol Carcinog. 1998 Jan; 21(1):2-12.
[Mol Carcinog. 1998]Oncogene. 2002 Jan 3; 21(1):53-64.
[Oncogene. 2002]Nucleic Acids Res. 2005 Jul 1; 33(Web Server issue):W616-20.
[Nucleic Acids Res. 2005]Biostatistics. 2003 Apr; 4(2):249-64.
[Biostatistics. 2003]Bioinformatics. 2003 Jan 22; 19(2):185-93.
[Bioinformatics. 2003]Biotechniques. 2003 Feb; 34(2):374-8.
[Biotechniques. 2003]Genome Biol. 2001; 2(10):RESEARCH0042.
[Genome Biol. 2001]Development. 2004 Jun; 131(11):2737-48.
[Development. 2004]Cancer Res. 2007 Nov 15; 67(22):10879-88.
[Cancer Res. 2007]Genome Biol. 2003; 4(5):P3.
[Genome Biol. 2003]Int J Dev Biol. 1999 Nov; 43(8):795-807.
[Int J Dev Biol. 1999]Nature. 2001 Mar 22; 410(6827):475-8.
[Nature. 2001]Trends Biochem Sci. 2002 Jul; 27(7):352-60.
[Trends Biochem Sci. 2002]Oncogene. 2006 Feb 23; 25(8):1174-85.
[Oncogene. 2006]J Invest Dermatol. 2003 Jan; 120(1):36-47.
[J Invest Dermatol. 2003]J Cell Biol. 2003 Nov 10; 163(3):609-23.
[J Cell Biol. 2003]Development. 2004 May; 131(10):2257-68.
[Development. 2004]Development. 2004 Apr; 131(8):1825-33.
[Development. 2004]Proc Natl Acad Sci U S A. 2005 Jan 4; 102(1):93-8.
[Proc Natl Acad Sci U S A. 2005]Dev Cell. 2002 May; 2(5):617-27.
[Dev Cell. 2002]Nature. 1999 Apr 22; 398(6729):708-13.
[Nature. 1999]Nature. 1999 Apr 22; 398(6729):714-8.
[Nature. 1999]J Biol Chem. 2003 Dec 19; 278(51):51408-14.
[J Biol Chem. 2003]Oncogene. 2006 Feb 23; 25(8):1174-85.
[Oncogene. 2006]Proc Natl Acad Sci U S A. 2006 Nov 28; 103(48):18166-71.
[Proc Natl Acad Sci U S A. 2006]Stem Cells. 2006 Dec; 24(12):2826-39.
[Stem Cells. 2006]Proc Natl Acad Sci U S A. 2007 Jun 12; 104(24):10063-8.
[Proc Natl Acad Sci U S A. 2007]Cell. 2006 Apr 21; 125(2):229-31.
[Cell. 2006]J Invest Dermatol. 2003 Nov; 121(5):963-8.
[J Invest Dermatol. 2003]Development. 2004 Jun; 131(11):2737-48.
[Development. 2004]Cancer Res. 2007 Nov 15; 67(22):10879-88.
[Cancer Res. 2007]Mol Cell. 2002 Oct; 10(4):721-33.
[Mol Cell. 2002]Genes Dev. 2003 Jun 1; 17(11):1352-65.
[Genes Dev. 2003]Mol Cell Biol. 2005 Dec; 25(23):10407-18.
[Mol Cell Biol. 2005]Cancer Res. 2003 Feb 1; 63(3):674-81.
[Cancer Res. 2003]Cell. 2007 Jun 29; 129(7):1261-74.
[Cell. 2007]Cancer Res. 2007 Nov 15; 67(22):10879-88.
[Cancer Res. 2007]Mech Dev. 2000 Mar 15; 92(1):19-29.
[Mech Dev. 2000]J Invest Dermatol. 2003 Jan; 120(1):36-47.
[J Invest Dermatol. 2003]Development. 2004 May; 131(10):2257-68.
[Development. 2004]J Cell Biol. 2003 Nov 10; 163(3):609-23.
[J Cell Biol. 2003]Proc Natl Acad Sci U S A. 2006 Nov 28; 103(48):18166-71.
[Proc Natl Acad Sci U S A. 2006]Hum Mol Genet. 2003 Mar 15; 12(6):679-84.
[Hum Mol Genet. 2003]Nat Genet. 2004 Oct; 36(10):1117-21.
[Nat Genet. 2004]Cell Cycle. 2005 Feb; 4(2):215-6.
[Cell Cycle. 2005]Stem Cells. 2006 Dec; 24(12):2826-39.
[Stem Cells. 2006]Proc Natl Acad Sci U S A. 2007 Jun 12; 104(24):10063-8.
[Proc Natl Acad Sci U S A. 2007]Am J Med Genet A. 2006 Dec 1; 140(23):2530-5.
[Am J Med Genet A. 2006]Differentiation. 2004 Oct; 72(8):364-70.
[Differentiation. 2004]Mol Endocrinol. 2004 Feb; 18(2):303-11.
[Mol Endocrinol. 2004]FASEB J. 2001 Sep; 15(11):2030-2.
[FASEB J. 2001]Endocrinology. 2005 Jun; 146(6):2629-38.
[Endocrinology. 2005]Mol Cell Neurosci. 2002 May; 20(1):21-9.
[Mol Cell Neurosci. 2002]J Cell Biochem. 2003 Jan 1; 88(1):24-8.
[J Cell Biochem. 2003]Trends Mol Med. 2006 Nov; 12(11):503-5.
[Trends Mol Med. 2006]Cell. 2006 Apr 21; 125(2):229-31.
[Cell. 2006]Nature. 2006 May 25; 441(7092):475-82.
[Nature. 2006]